WO2004103277A2 - Nouvelle composition d'equilibre hormonal et ses utilisations - Google Patents

Nouvelle composition d'equilibre hormonal et ses utilisations Download PDF

Info

Publication number
WO2004103277A2
WO2004103277A2 PCT/US2004/014658 US2004014658W WO2004103277A2 WO 2004103277 A2 WO2004103277 A2 WO 2004103277A2 US 2004014658 W US2004014658 W US 2004014658W WO 2004103277 A2 WO2004103277 A2 WO 2004103277A2
Authority
WO
WIPO (PCT)
Prior art keywords
clover
composition
composition according
chasteberry
black cohosh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/014658
Other languages
English (en)
Other versions
WO2004103277A3 (fr
Inventor
Dilip Chokshi
Mitchell Skop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmachem Laboratories Inc
Original Assignee
Pharmachem Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachem Laboratories Inc filed Critical Pharmachem Laboratories Inc
Priority to EP04751854A priority Critical patent/EP1622590A2/fr
Priority to CA002521558A priority patent/CA2521558A1/fr
Publication of WO2004103277A2 publication Critical patent/WO2004103277A2/fr
Publication of WO2004103277A3 publication Critical patent/WO2004103277A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)

Definitions

  • the present invention relates to the mitigation of symptoms associated with female reproductive hormones.
  • menopause During menopause, the woman can experience wide fluctuations in baseline hormonal levels. The erratic hormone levels associated with menopause can cause a wide variety of symptoms. These symptoms can last from six months to two years. The symptoms can include hot flashes, sweating, heart palpitations, headaches, cramping, nausea, and mood swings.
  • the woman becomes susceptible to certain conditions. For example, the body's ability to maintain calcium levels is compromised which results in an increased loss of minerals from the bones (e.g., osteoporosis).
  • bones e.g., osteoporosis
  • HRT hormone replacement therapy
  • synthetic estrogens and or progesterones can be effective in suppressing the symptoms of menopause, such as hot flashes, and may 'be effective in reducing calcium loss, and preserving bone density.
  • side effects such as, for example, mastalgia, edema/ abdominal bloating, and increase in the size of uterine leiomyomata have been associated with the use of HRT.
  • cancers such as breast cancer and ' endometrial cancer have also been associated with HRT.
  • HRT hormone replacement therapy
  • U.S. Patent No. 6,497,885 to Trant discloses a composition containing
  • Vitex agnus-castus (chasteberry), antioxidants, L-arginine, folic acid, vitamin B6, iron, zinc, and magnesium.
  • the present invention addresses the above need by providing a composition containing specifically selected ingredients that have minimal adverse side effects and/or risks, and that can be optionally enrobed in a glycoprotein matrix, for promoting hormonal balance.
  • composition consisting essentially of a soy component, chasteberry, clover, and black cohosh, in a suitable carrier.
  • the invention provides a composition consisting essentially of a soy component, chasteberry, clover, and black cohosh, in a suitable carrier, wherein each of the soy component, chasteberry, clover, and black cohosh is enrobed in a glycoprotein matrix.
  • the invention provides a method for promoting hormonal balance in a woman in need thereof.
  • the method comprises administering to the woman an effective amount of a composition consisting essentially of a soy component, chasteberry, clover, and black cohosh, in a suitable carrier.
  • the invention provides " a method for promoting hormonal balance in a woman in need thereof.
  • the method comprises administering to the woman an effective amount of a composition consisting essentially. of a soy component, chasteberry, clover, and black cohosh, in a suitable carrier, wherem each of the soy component, chasteberry, clover, and black cohosh is enrobed in a glycoprotein matrix, and
  • a composition which consists essentially of a soy component, chasteberry, clover, and black cohosh in a suitable carrier.
  • the composition promotes hormonal balance in a woman in need thereof.
  • the soy component can be any component derived from a soybean.
  • the soybean is non-genetically modified (non-GMO) organic soybean.
  • Organic soy as used herein means that the soy component is derived from soybeans that are grown without synthetic pesticides and fertilizers.
  • Soybeans typically contain high levels of isoflavones and protein.
  • An example of a soy component useful in the present invention are soy proteins.
  • the soy component is isoflavones
  • Isoflavones belong to the family of phytoestrogens, which are compounds that typically mimic estrogen.
  • a suitable soy component is also defatted, non-genetically engineered
  • Chasteberry is a berry obtained from a chaste tree. Chasteberry is botanically known as Vitex agnus-castus. Other common names for chasteberry include, for example, vitex, monk's pepper, and chaste tree berry. Chasteberry is a medicinal herb which generally contains phytohormones. The herb typically influences hormonal activity by stimulating the pituitary gland to produce more luteinizing hormone.
  • the chasteberry component contains a combination of one or more of iridoids, flavanoids and terpenoids.
  • Clover is a plant that commonly grows in Europe and North America.
  • the clover can be any variety of clover, such as red clover and white clover.
  • the clover is red clover.
  • Red clover is botanically known as Trifolium pretense and contains high levels of isoflavone compounds, such as genistein.
  • Black cohosh is a perennial plant that is a member of the buttercup family. Black cohosh is botanically known as Actaea racemosa and Cimicifuga racemosa. Other common names for black cohosh include black snakeroot, bugbane, bugwort, rattleroot, rattletop, rattleweed, and macrotys. Preparations of black cohosh are typically made from roots and rhizomes.
  • the black cohosh component contains terpenoids and/or flavanoids.
  • the active component of soybean, chasteberry, red clover, and black cohosh can be from any part of the plant (e.g., stem, leaves, flowers, seed, roots, or rhizome). It is known in the art where the active component is located in soybean, chasteberry, red clover, and black cohosh. For example, the active component is preferably obtained from the roots and rhizome of black cohosh, and from the flowers of red clover.
  • the active component can be extracted and concentrated into a liquid or solid form.
  • the extraction and concentration of the active component of soybean, chasteberry, red clover, and black cohosh can be done by any method known to those skilled in the art.
  • the active component can be extracted using, supercritical extraction methods.
  • supercritical extraction involves the use of a supercritical fluid, such as. carbon dioxide, for extraction.
  • the active component is not crucial to extract and concentrate the active component from soybean, chasteberry, red clover, and black cohosh.
  • parts of the plant e.g., soybean, chasteberry, red clover, or black cohosh
  • the roots and rhizome of black cohosh can be dried and ground into a powder for use in the composition.
  • the composition can contain essentially any amount of soybean, chasteberry, red clover, and black cohosh as desired.
  • the percentage of soybean, chasteberry, red clover, and black cohosh can vary between 0.1 and 99.9% by weight of the composition.
  • composition contains no other ingredients that can promote hormonal balance.
  • other components such as stabilizers, surfactants, salts, buffering agents, etc., described below, can be included in a formulation (e.g., tablets, gelatin capsules, pills, troches, elixirs, caplets, powders, granules, sachets, suspensions, syrups, wafers, chewing gum) of the composition.
  • composition can be formulated with suitable carriers, such as inert, inorganic or organic carriers.
  • suitable carriers include, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like, water, polyols, saccharose, invert sugar, glucose and the like, alcohols, and glycerin.
  • a composition which consists essentially of a soy component, chasteberry, clover, and ' black cohosh in a suitable . carrier, wherein each of the ingredients (i.e., soy component, chasteberry, clover, and black cohosh) is enrobed in a glycoprotein matrix.
  • glycoprotein matrix and ingredient can be associated with each other physically and/or chemically, such as by chemical reaction, and/or secondary chemical bonding, e.g], Van der Waals forces, hydrogen bonds, etc. It is believed that glycoprotein matrix associates with the ingredient by weak covalent bonds. Due to the association between the glycoprotein matrix and the ingredient, the ingredient is enrobed (e.g., coated, encapsulated) with a glycoprotein matrix.
  • the glycoprotein matrix is the glycoprotein to which the ingredient is enrobed.
  • Glycoprotein is a composite material typically made of one or more carbohydrate groups and a simple protein.
  • a glycoprotein matrix is a molecular network comprised of a plurality of glycoprotein molecules bound together.
  • the carbohydrate in the glycoprotein can be any suitable carbohydrate, such as a monosaccharide, disaccharide, oligosaccharide, or polysaccharide. Oligosaccharide is preferred.
  • the protein of the glycoprotein can any suitable polypeptide.
  • the ratio of carbohydrate to protein in the glycoprotein matrix can vary, for example, from 99:1 to 1:99 by weight. A ratio of approximately 1:1 is preferred.
  • the ratio of glycoprotein matrix to the ingredient can also vary. It is preferred that the ratio of glycoprotein matrix to the ingredient will be such that all or nearly all of the ingredient is bound by glycoprotein matrix. Such amounts can be readily determined by the skilled practitioner.
  • glycoprotein matrix to ingredient can be used.
  • the invention also contemplates that there may be insufficient glycoprotein to bind all of the ingredient. . In such cases, the ratio of glycoprotein matrix to ingredient can be less.
  • the glycoprotein matrix is derived from one or more strains of microorganisms
  • a microorganism is typically any microscopic organism, such as bacteria, algae, fungi, and protozoa.
  • the microorganisms can be naturally occurring strains of laboratory-bred strains.
  • Microorganisms that produce a glycoprotein matrix include, but are not limited to, yeast (e.g., fungi) and bacteria.
  • yeast e.g., fungi
  • bacteria e.g., Saccharomyces cervisiae.
  • Bacteria useful in the present invention for producing glycoprotein matrix can be any bacteria.
  • the bacteria functions as a probiotic.
  • a probiotic is typically a microbial supplement which beneficially improves intestinal microbial balance.
  • probiotics can aid in digestion and can help prevent illness by promoting the growth of good bacteria in a digestive host.
  • Bacteria which are useful as probiotics include probiotics within the genus Lactobacillus.
  • probiotics include, but are not limited to, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus caucasicus, and Bacterium bifidus.
  • Preferred probiotics include Lactobacillus acidophillus and Bacterium bifidus.
  • One or more strains of microorganisms can be used provided that at least one of the microorganisms produces glycoprotein. ' When using combinations of microorganisms, the growth of one type of microorganism should not prevent the growth of the other. For example, various types of different yeast that produce glycoprotein can be used. Also, yeast and bacteria can be combined to produce glycoprotein. This combination is particularly advantageous because various types of* bacteria, such as Lactobacillus acidophillus, also produce glycoprotein.
  • an ingredient can be enrobed with a glycoprotein matrix by allowing the microorganism to ferment, in the presence of the ingredient.
  • fermentation is the process by which microorganisms metabolize raw materials, such as amino acids and carbohydrate, to produce glycoprotein.
  • the microorganisms produce glycoprotein both intracellularly and extracellularly
  • the intracellular glycoprotein will mainly be located in the cytoplasm of the microorganism or become part of the microorganism's physical structure.
  • the glycoprotein from the microorganism that forms the glycoprotein matrix is mainly extracellular and, therefore, is available to be bound to the ingredient.
  • Intracellular glycoprotein can also be made accessible for binding to ingredient by rupture of the microorganisms after glycoprotein production. At the end of the manufacturing process of enrobing an ingredient with a glycoprotein matrix, these microorganisms are usually inactive.
  • the microorganism used to produce the glycoprotein matrix should be suitable for consumption by humans.
  • examples of such microorganisms include Lactobacillus acidophillus and Saccharomyces cervisiae.
  • the ingredient can be enrobed in a glycoprotein matrix by any method known in the art.
  • Methods for enrobing substances, such as vitamins and minerals, with a glycoprotein matrix are disclosed in U.S. Patent Application Serial Nos. 09/906,576 and 09/757,222.
  • the specification of U.S. Patent Application Serial Nos. 09/906,576 and 09/757,222 are hereby incorporated by reference.
  • a method for enrobing an ingredient with a glycoprotein matrix includes contacting the ingredient with a glycoprotein producing microorganism under conditions in which the microorganism produces glycoprotein.
  • the microorganisms require a medium in which to ferment and produce glycoprotein. Such media are known to those skilled in the art, and are usually liquid. Water is preferred.
  • the microorganism solution should contain enough growth medium so as to allow for efficient growth of the microorganisms, as is known in the art. When the microorganisms are added to the liquid medium, a microorganism solution is formed.
  • a microorganism solution is prepared in which the microorganisms will, produce glycoprotein.
  • the number of colony forming units of microorganism added to the medium will vary based upon the type of microorganism used.
  • a sufficient amount of colony forming units should be added to the microorganism solution to enrobe at least some of the ingredient. If the composition of the invention is to contain a small amount of ingredient, fewer microorganisms will be required to bind the ingredient with glycoprotein matrix. It is preferred that enough colony forming units be added to the microorganism solution to bind essentially all of the ingredient with glycoprotein matrix. ' One skilled in the art can determine such amounts.
  • the amount of colony forming units of the microorganism utilized can also depend upon the molecular weight and amount of the ingredient in the composition. For example, more colony forming units are necessary to fully bind a higher molecular weight ingredient. Fewer colony forming units are required for a low molecular weight ingredient.
  • the microorganisms that produce the glycoprotein typically require nutrients to efficiently grow, multiply, and form glycoprotein by metabolizing the nutrients.
  • the nutrients can be directly added to the microorganism solution or can be added to a nutrient media, which is then added to the microorganism solution.
  • Amino acids are one nutrient that may be necessary for efficient glycoprotein production.
  • the amino acids are metabolized by the microorganisms and ultimately become part of the polypeptide within the glycoprotein matrix.
  • the amino acids should include those that are suitable for the manufacture of glycoprotein.
  • Such amino acids include, but are not limited to, glutamine, lysine, cysteine and methionine, aspartic acid, leucine, valine, alanine, arginine, and glycine.
  • the amino acids need not be in a pure form, but can be added as part of a stable compound. Examples of amino acid compounds that can be used are L-Glutamic Acid, L-Lysine HC1, L-Cysteine HC1 and DL-Methionine.
  • the amount of amino acids will vary based upon the amount, molecular weight, and percentage of ingredient desired to be enrobed by glycoprotein matrix. If the ingredient is a small molecular weight molecule, it may not be necessary to add amino acids as a nutrient for the production of glycoprotein matrix by the microorganisms.
  • Carbohydrate is a nutrient that is added for the efficient production of glycoprotein by the microorganism. As with the amino acids, the carbohydrate can be added to a nutrient media, which is then added to the microorganism solution, or can be added directly to the microorganism solution. Carbohydrates beneficial for the production of glycoprotein are known in the art.
  • the carbohydrate can be, for example, a polysaccharide, oligosaccharide, disaccharide or monosaccharide or combinations thereof. Examples of appropriate carbohydrates include, but are not limited to, maltose and gum acacia. Maltose is most preferred.
  • the amount of carbohydrate added to the nutrient media or microorganism solution will vary depending upon the complexity and molecular weight of the carbohydrate added to the solution.
  • The. amount of carbohydrate should be sufficient to permit the microorganisms to produce the glycoprotein matrix.
  • the amount of carbohydrate necessary will also vary based upon the amount and percentage of ingredient desired to be bound by glycoprotein matrix.
  • the microorganism solution will contain the ingredient to be bound by glycoprotein matrix.
  • the ingredient is added before or after fermentation of the microorganisms begins, If the ingredient is added after fermentation, it is preferred that the ingredient is added immediately after fermentation of the microorganisms begins.
  • the- invention provides a method for promoting hormonal balance in a woman in need thereof, by administering to the woman an effective amount of a composition described above.
  • the term "effective amount” as used herein is the amount that is sufficient for promoting hormonal balance (e.g., alleviate symptoms, described above,_ of hormonal imbalance).
  • the effective amount can be determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians.
  • An effective amount, preferably in a pharmaceutical composition, may be administered to a woman in need thereof by any of a number of well-known methods for administering pharmaceutical compounds.
  • the soybean component, chasteberry, clover, and black cohosh can be mixed with a suitable pharmaceutical carrier (vehicle) or excipient as understood by practitioners in the art.
  • suitable pharmaceutical carrier include starch, milk, sugar, certain types of clay, gelatin, lactic acid, stearic acid or salts thereof, including magnesium or calcium stearate, talc, vegetable fats or oils, gums and glycols.
  • composition may be administered to a woman by sustained release, as is known in the art.
  • Sustained release administration is a method of drug delivery to achieve a certain level of the drug over a particular period of time. The level typically is measured by serum concentration.
  • any formulation known in the art of pharmacy is suitable for administration of the composition.
  • Some examples of formulations include tablets, gelatin capsules, pills, troches, elixirs, caplets, powders, granules, sachets, suspensions, syrups, wafers, chewing gum, soft chews, and the like.
  • liquid or solid formulations may be used.
  • the ingredients are in a soft chew.
  • Soft chews are soft, chewable confections that have a nougat candy consistency.
  • the confection imparts a soft, yet unsticky chew texture.
  • Such a confection can be obtained by any known method, so long as the use of high heat, excessive moisture and dehydration processes are avoided.
  • composition of the invention in a soft chew will be more potent. Unlike tablet formulations, by avoiding the use of high heat, excessive moisture and compression, the ingredients in the soft chew are minimally disturbed. Therefore, the soft chew will provide the ingredients in a more bioactive . form.
  • formulations of the composition may utilize conventional diluents, carriers, or. excipients etc., such as are known in the art can be employed.
  • the formulations may comprise one or more of the following: a stabilizer, a surfactant, •preferably a nonionic surfactant, and optionally a salt and/or a buffering agent.
  • the composition may be delivered in the form of an aqueous solution, or in a lyophilized form.
  • the stabilizer may, for example, be an amino acid, such as for instance, glycine; or an oligosaccharide, such as for example, sucrose, tetralose, lactose or a dextran.
  • the stabilizer may be a sugar alcohol, such as for instance, mannitol; or a combination thereof.
  • the stabilizer or combination of stabilizers constitutes from about 0.1% to about 10% weight for weight of the composition.
  • the surfactant is preferably a nonionic surfactant, such as a polysorbate.
  • Suitable surfactants include Tween20, Tween80; a polyethylene glycol or a polyoxyethylene polyoxypropylene glycol, such, as Pluronic F-68 at from about 0.001% (w/v) to about 10% (w/v).
  • the salt or buffering agent may be any salt or buffering agent, such as for example, sodium chloride, or sodium/potassium phosphate, respectively.
  • the buffering agent maintains the pH of the pharmaceutical composition in the range of about 5.5 to about 7.5.
  • the salt and/or buffering agent is also useful to maintain the osmblality at a level suitable for administration to a human or an animal. •
  • the salt or buffering agent is present at a roughly isotonic concentration of about 150mM to about 300mM.
  • the formulations of the composition may additionally contain one or more conventional additives.
  • additives include a solubilizer such as, for example, glycerol; an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as "quats"), benzyl alcohol, chloretone or chlorobutanol; anaesthetic agent such as for example a morphine derivative; or an isotonic agent etc., such as described above.
  • a solubilizer such as, for example, glycerol
  • an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as "quats"), benzyl alcohol, chloretone or chlorobutanol
  • anaesthetic agent such as for example a morphine derivative
  • an isotonic agent etc. such as described above.
  • the pharmaceutical compositions may be stored under nitrogen gas in vials sealed with impermeable stoppers.
  • Women in need of promoting hormonal balance include those, women who are suffering from hormonal imbalance.
  • women suffering from hormonal imbalance include, for example, peri-menopausal women, menopausal women, women with erratic menstrual cycles, women suffering from post-partum depression, women in which menstruation has ceased for any reason, including for example hysterectomy, ovarian failure, ovarian removal, chemotherapy, radiation, etc.
  • This example demonstrates the preparation of soy plus glycoprotein matrix (GPM) complex to yield a soy + GPM complex.
  • the method employs preparing, in a first container, an aqueous solution of soy and adding a peptone made of amino acids.
  • an active yeast solution is prepared. Active baker's yeast, Saccharomyces cervisiae is added to water to form an aqueous solution. Maltose and gum acacia are then added.
  • the first container containing the soy is then inoculated very slowly into the active yeast solution to form a live fermented solution.
  • the mixture is allowed to ferment for four to six hours.
  • plant proteins and carbohydrates are added.
  • Proteolytic enzyme such as papain, is then added.
  • Lactobacillus acidophillus is added to the live fermented solution and allowed to ferment for about 2 hours. Active fermentation is then stopped by heating the solution to 160-170°F for three hours. .
  • the fermented solution containing soy is then homogenized in a . shearing pump (Charles Ross & Sons Corp.) for approximately 1-2 hours and spray dried (NIRO, Nicholas Engineers Research Corp.) for approximately 4 hours.
  • the resulting product is a powder containing the soy + GPM complex.
  • This example demonstrates the preparation of chasteberry plus glycoprotein matrix (GPM) complex to yield chasteberry + GPM complex.
  • the method employs preparing, in a first container, an aqueous solution of chasteberry and adding a peptone made of amino acids.
  • an active yeast solution is prepared. Active baker's yeast, Saccharomyces cervisiae is added to water to form an aqueous solution. Maltose and gum acacia are then added.
  • the first container containing the chasteberry is then inoculated very slowly into the active yeast solution to form a live fermented solution.
  • the mixture is allowed to ferment for four to six hours.
  • plant proteins and carbohydrates are added.
  • Proteolytic enzyme, such as papain, is then added.
  • Lactobacillus acidophillus is added to the live fermented solution and allowed to ferment for about 2 hours. Active fermentation is. then stopped by heating the solution to 160-170°F for three hours.
  • the fermented solution containing chasteberry is then homogenized in a shearing pump (Charles Ross & Sons Corp.) for approximately 1-2 hours and spray dried (NIRO, Nicholas Engineers Research Corp.) for approximately 4 hours.
  • the resulting product is a powder containing the chasteberry GPM complex.
  • This example demonstrates the preparation of clover plus glycoprotein matrix (GPM) complex to yield clover + GPM complex.
  • the method employs preparing, in a first container, an aqueous solution of clover and adding a peptone made of amino acids.
  • an active yeast solution is prepared. Active baker's yeast, Saccharomyces cervisiae is added to water to form an aqueous solution. Maltose and gum acacia are then added.
  • the first container containing the clover is then inoculated very slowly into the active yeast solution to form a live fermented solution.
  • the mixture is allowed to ferment for four to six hours.
  • plant proteins and carbohydrates are added.
  • Proteolytic enzyme such as papain, is then added.
  • Lactobacillus acidophillus is added to the live fermented solution and allowed to ferment for about 2 hours. Active fermentation is then stopped by heating the solution to 160- 170°F for three' hours.
  • the fermented solution containing clover is then homogenized in a shearing pump (Charles Ross & Sons Corp.) for approximately 1-2 hours and spray dried (NTRO, Nicholas Engineers Research Corp.) for approximately 4 hours.
  • the resulting product is a powder containing the clover GPM complex.
  • This example demonstrates the preparation of black cohosh plus glycoprotein matrix (GPM) complex to yield black cohosh + GPM complex.
  • the method employs, preparing, in a first container, an aqueous solution of black cohosh and adding a peptone made of amino acids.
  • an active yeast solution is prepared. Active baker's yeast, Saccharomyces cervisiae is added to water to form an aqueous solution. Maltose and gum acacia are then added.
  • the first container containing the black cohosh is then inoculated very slowly into the active yeast solution to form a live fermented solution.
  • the mixture is allowed to ferment for four to six hours.
  • plant proteins and carbohydrates are added.
  • Proteolytic enzyme, such as papain, is then added.
  • Lactobacillus acidophillus is added to . the live fermented solution and allowed to ferment for about 2 hours. Active fermentation is then stopped by heating the solution to 160-170°F for three hours.
  • the fermented solution containing black cohosh is then homogenized in a shearing pump (Charles Ross & Sons Corp.) for approximately 1-2 hours and spray dried (NIRO, Nicholas Engineers Research Corp.) for approximately 4 hours.
  • the resulting product is a powder containing the black cohosh GPM complex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne une composition et des méthodes d'utilisation de cette composition constituée essentiellement par soja, vitex agnus-castus, trèfle et cohoch noir dans un véhicule approprié, chacun de ces constituants étant éventuellement enrobé dans une matrice de glycoprotéine.
PCT/US2004/014658 2003-05-12 2004-05-11 Nouvelle composition d'equilibre hormonal et ses utilisations Ceased WO2004103277A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04751854A EP1622590A2 (fr) 2003-05-12 2004-05-11 Nouvelle composition d'equilibre hormonal et ses utilisations
CA002521558A CA2521558A1 (fr) 2003-05-12 2004-05-11 Nouvelle composition d'equilibre hormonal et ses utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/435,949 US20040228931A1 (en) 2003-05-12 2003-05-12 Novel composition for hormonal balance and uses thereof
US10/435,949 2003-05-12

Publications (2)

Publication Number Publication Date
WO2004103277A2 true WO2004103277A2 (fr) 2004-12-02
WO2004103277A3 WO2004103277A3 (fr) 2005-03-24

Family

ID=33417050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014658 Ceased WO2004103277A2 (fr) 2003-05-12 2004-05-11 Nouvelle composition d'equilibre hormonal et ses utilisations

Country Status (4)

Country Link
US (1) US20040228931A1 (fr)
EP (1) EP1622590A2 (fr)
CA (1) CA2521558A1 (fr)
WO (1) WO2004103277A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039971A1 (en) * 2004-08-19 2006-02-23 Lee Robert E Effervescent composition including alternative hormone replacement therapy agent
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same
US8709977B2 (en) * 2009-03-23 2014-04-29 Donaghys Industries Limited Bio-stimulant for improved plant growth and development
PT2931270T (pt) 2012-12-12 2020-10-26 Herrens Mark Aps Extrato de trevo vermelho fermentado e método para produzir o mesmo
US10137164B2 (en) 2015-01-02 2018-11-27 Melaleuca, Inc. Dietary supplement compositions
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
TWI759260B (zh) * 2015-01-02 2022-04-01 美商梅拉洛伊卡公司 多元補充品組成物
RU2736997C1 (ru) * 2019-07-30 2020-11-23 Общество С Ограниченной Ответственностью "Парафарм" Средство для лечения приливов и восстановления менструального цикла в период перименопаузы и способ его применения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656786B2 (fr) * 1992-05-19 2014-04-23 Novogen Research Pty Ltd Utilisation d'extraits des phyto-estrogenes d'isoflavones à partir de soja ou de trèfle
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
US6242012B1 (en) * 1999-10-19 2001-06-05 Thomas Newmark Herbal composition for promoting hormonal balance in women and methods of using same
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans

Also Published As

Publication number Publication date
US20040228931A1 (en) 2004-11-18
WO2004103277A3 (fr) 2005-03-24
EP1622590A2 (fr) 2006-02-08
CA2521558A1 (fr) 2004-12-02

Similar Documents

Publication Publication Date Title
US20230270142A1 (en) Composition containing equol and ornithine
US5547671A (en) Anti-intoxication composition
KR101826673B1 (ko) 더덕 추출물을 함유하는 장 건강 개선용 조성물
US20040228931A1 (en) Novel composition for hormonal balance and uses thereof
CN110150667A (zh) 一种提升免疫力并调节肠道功能的保健品及其制备方法
KR20150005430A (ko) 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물
KR20070039924A (ko) 석류액, 석류액 분말 및 분말 생산 공정
US7138113B2 (en) Glycoprotein matrix compositions and methods related thereto
JP4371431B2 (ja) 抗アレルギー性組成物
JP2006256968A (ja) 骨代謝改善剤とその製造方法
US20020114786A1 (en) Pharmaceutical preparations comprising soybean isoflavone extracts and probiotic microogranisms
KR20110093513A (ko) 산나물 추출물을 함유하는 여성 폐경기 증후군 예방 및 치료용 조성물
WO2008124994A1 (fr) Additif alimentaire de protection de l'environnement pour volailles et animaux domestiques et son procédé de préparation
WO2022010387A1 (fr) Utilisation d'une préparation à base de plante polyscias filicifolia pour le traitement d'affections des fonctions élémentaires
EP1875920A2 (fr) Extraits de soja total partiellement dénaturé et procédé d'utilisation correspondant
KR100771987B1 (ko) 테스토스테론 분비 증강 효과를 갖는 복분자 추출물을유효 성분으로 함유한 조성물
CN100479830C (zh) 一种保健品组合物及其制备和应用
US20230371563A1 (en) Fermented avocado granulate and food supplements containing it
KR20100073293A (ko) 둥근마 조추출물 또는 분획물을 유효성분으로 함유하는비만증의 예방 및 치료용 조성물
KR20230072666A (ko) 시트러스 발효 추출물을 유효성분으로 함유하는 뼈 건강 개선용 조성물
HK1259202B (en) A method for producing an equol- and ornithine-containing fermented soybean hypocotyl material
HK1259202A1 (en) A method for producing an equol- and ornithine-containing fermented soybean hypocotyl material
KR20190091198A (ko) 효소처리 로얄젤리 분말을 유효성분으로 포함하는 면역기능 증진용 약학적 조성물
US20080161385A1 (en) Composition Inhibiting Sex Hormone-Binding Globulin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521558

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004751854

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004751854

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004751854

Country of ref document: EP